Alkermes ALKS
NASDAQ ALKS
$45.39 -0.10 (-0.22%)
As of: Sep 9, 2026 · 12:35 PM EDT

Alkermes (ALKS) Shares Outstanding (2010 - 2026)

Alkermes' (ALKS) quarterly Shares Outstanding (Entity) came in at $167.5 million in Q2 2026, up 1.51% year-over-year from $165.1 million in Q2 2025, and up 0.65% quarter-over-quarter from $166.5 million in Q1 2026.

Analysis

Alkermes (ALKS) Shares Outstanding (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Shares Outstanding (Entity) for 17 consecutive years, with $167.5 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Shares Outstanding (Entity) rose 1.51% year-over-year to $167.5 million in Q2 2026; TTM through Jun 2026 was $167.5 million, a 1.51% increase from a year earlier, with the FY2025 full-year figure at $165.6 million, up 2.11% from the prior year.
  • Shares Outstanding (Entity) was $167.5 million for Q2 2026 at Alkermes, up from $166.5 million in the prior quarter.
  • Over five years, Shares Outstanding (Entity) peaked at $169.2 million in Q1 2024 and troughed at $161.8 million in Q3 2024.
  • A 5-year average of $165.3 million and a median of $165.4 million in 2025 frame the typical range for Shares Outstanding (Entity).
  • Across the five-year window, Shares Outstanding (Entity) declined 2.96% in 2024 and climbed 2.11% in 2025, its largest moves.
  • Over 5 years, Shares Outstanding (Entity) stood at $164.4 million in 2022, then rose by 1.58% to $167.0 million in 2023, then dropped by 2.88% to $162.2 million in 2024, then advanced by 2.11% to $165.6 million in 2025, then increased by 1.17% to $167.5 million in 2026.
  • The last three Shares Outstanding (Entity) figures came in at $167.5 million (Q2 2026), $166.5 million (Q1 2026), and $165.6 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Outstanding (Qtr)
1 Johnson & Johnson 644.82 Bn 624.06 Bn 17.26 Bn 2.41 Bn
2 AbbVie 440.98 Bn 434.41 Bn 12.70 Bn 1.77 Bn
3 Merck 364.65 Bn 357.51 Bn 12.21 Bn 2.47 Bn
4 Novartis Ag 266.52 Bn 258.83 Bn 11.24 Bn 1.94 Bn
5 Pfizer 158.95 Bn 147.25 Bn 10.94 Bn 5.70 Bn
6 Sanofi 52.51 Bn 45.13 Bn 10.79 Bn 1.22 Bn
7 Revolution Medicines 44.17 Bn 44.17 Bn - 210.89 Mn
8 Incyte 25.25 Bn 20.71 Bn 1.57 Bn 200.38 Mn
9 United Therapeutics 21.44 Bn 18.78 Bn 683.80 Mn 42.60 Mn
10 Alkermes 7.58 Bn 6.92 Bn 397.90 Mn 167.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 167.03 Mn
Mar 31, 2026 166.20 Mn
Dec 31, 2025 164.70 Mn
Sep 30, 2025 165.09 Mn
Jun 30, 2025 164.96 Mn
Mar 31, 2025 163.41 Mn
Dec 31, 2024 165.39 Mn
Sep 30, 2024 163.37 Mn
Jun 30, 2024 168.32 Mn
Mar 31, 2024 167.98 Mn
Dec 31, 2023 166.22 Mn
Sep 30, 2023 166.61 Mn
Jun 30, 2023 166.28 Mn
Mar 31, 2023 165.09 Mn
Dec 31, 2022 163.54 Mn
Sep 30, 2022 164.28 Mn
Jun 30, 2022 163.84 Mn
Mar 31, 2022 162.48 Mn
Dec 31, 2021 160.94 Mn
Sep 30, 2021 161.46 Mn